ArticleBreast cancer research and treatment2020
The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative.
Article in Breast cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Quantifying the impact of treatment delays on breast cancer survival outcomes: a comprehensive meta-analysis.GeroScience · 2026Pooled it
- Pooled it
- Impact of Second Opinions on Time to Treatment of Breast Cancer.Annals of surgical oncology · 2025Article
- Surgeon and Care Team Network Measures and Timely Breast Cancer Treatment.JAMA network open · 2024Article
- The Association Between Oncology Outreach and Timely Treatment for Rural Patients with Breast Cancer: A Claims-Based Approach.Annals of surgical oncology · 2024Article
- Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.Breast cancer research and treatment · 2024Article
- Therapy delay due to COVID-19 pandemic among European women with breast cancer: prevalence and associated factors.Journal of cancer research and clinical oncology · 2023Article
- Incidence of COVID-19 in cancer patients in a teaching hospital faculty of medicine, in Medan, Indonesia.IJID regions · 2023Article
- Assurance of Timely Access to Breast Cancer Diagnosis and Treatment by a Regional Breast Health Clinic Serving Both Urban and Rural-Remote Communities.Current oncology (Toronto, Ont.) · 2023Article
- Breast Cancer Treatment in Integrated Care Process in Andalusia: The Challenge of Multidisciplinarity.International journal of environmental research and public health · 2022Article
- Psychotropic medication use and Parkinson's disease risk amongst older women.Annals of clinical and translational neurology · 2022Article
- Factors Influencing Delayed Treatment in Patients With Breast Cancer During COVID-19 Pandemic.Frontiers in public health · 2022Article
- An appropriate treatment interval does not affect the prognosis of patients with breast Cancer.Holistic integrative oncology · 2022Review
- Superparamagnetic Iron Oxide for Identifying Sentinel Lymph Node in Breast Cancer after Neoadjuvant Chemotherapy: Feasibility Study.Journal of clinical medicine · 2021Article
- Covid-19 related oncologist's concerns about breast cancer treatment delays and physician well-being (the CROWN study).Breast cancer research and treatment · 2021Article
- Breast cancer: are long-term and intermittent endocrine therapies equally effective?Journal of cancer research and clinical oncology · 2020Review
- Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.The oncologist · 2020Article
- Up-front Hypofractionated Radiotherapy Before Third-Generation Chemotherapy in Node-positive Breast Cancer: A Retrospective Comparative Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeDelays in adjuvant breast cancer (BC) therapy have been shown to worsen outcomes. However, thus far studies have only evaluated delays to initial treatment, or a particular modality, such as chemotherapy, leaving uncertainty about the role of delay to subsequent therapy and the effects of cumulative delay, on outcomes. We investigated the associations of delays across treatment modalities with survival.
methodsWe included 3368 women with incident stage I-III BC in the Women's Health Initiative (WHI) enrolled in fee-for-service Medicare who underwent definitive surgery. This prospective analysis characterized treatment delays by linking WHI study records to Medicare claims. Delays were defined as > 8 weeks to surgery, chemotherapy, and radiation from diagnosis or prior treatment. We used Cox proportional hazards models to estimate BC-specific mortality (BCSM) and all-cause mortality (ACM) in relation to treatment delays.
resultsWe found 21.8% of women experienced delay to at least one therapy modality. In adjusted analysis, delay to chemotherapy was associated with a higher risk of BCSM (HR = 1.71; 95% CI 1.07-2.75) and ACM (HR = 1.39; 95% CI 1.02-1.90); delay in radiation increased BCSM risk (HR = 1.49; 95% CI 1.00-2.21) but not ACM risk (HR = 1.19; 95% CI 0.99-1.42). Delays across multiple treatment modalities increased BCSM risk threefold (95% CI 1.51-6.12) and ACM risk 2.3-fold (95% CI 1.50-3.50).
conclusionsA delay to a single treatment modality and delay to a greater extent an accumulation of delays were associated with higher BCSM and ACM after BC. Timely care throughout the continuum of breast cancer treatment is important for optimal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.